MedTrace Logo

Avatrombopag on the Treatment of Thrombocytopenia Induced by Chemotherapy of Malignant Tumors

NCT04609891 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 74

Last updated 2022-04-29

No results posted yet for this study

Summary

To observe the clinical efficacy and safety of avatrombopag for chemotherapy-induced thrombocytopenia in patients with malignant tumors.

Conditions

Interventions

DRUG

Avatrombopag

10×109/L\<PLT\<75×109/L, avatrombopag tablet 60 mg once a day for 5-10 days.

Sponsors & Collaborators

  • Anhui Provincial Cancer Hospital

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-26
Primary Completion
2021-05-16
Completion
2021-05-16

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04609891 on ClinicalTrials.gov